JPRN-UMIN000010681已完成2 期
Multicenter randomized phase II study of cisplatin+pemetrexed+bevacizmab followed by maintenance pemetrexied with or without bevacizmab in patients chemoterapy-naive advanced non-squamous non-small cell lung cancer with wild type EGFR(TORG1321) - Randomized phase II study of CDDP+PEM+BEV followed by maintenance PEM with or without BEV in patients with chemotherapy-naive advanced non-squamous NSCLC with wild type EGFR(TORG1321)
Thoracic Oncology Tesearch Group0 个研究点目标入组 108 人开始时间: 2013年5月17日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •First step(induction) 1)Symptomatic brain metastasis 2)Current history of hemoptysis 3)With pulmonary cavity lesions 4)History of radical thoracic radiotherapy 5)Active infections diseases 6)Fever over 38 degrees centigrade 7)Serious complications 8)Massive pleural and cardiac effusion and ascites that need to be immediately treated 9)Active concomitant cancers 10)Severe drug allergy 11)Uncontrollable ulcer indigestive tract 12)Perforation of the digestive tract or history within the past one year 13)Receiving anticoagulant drug (325mg and less aspirin is possible) 14) Pregnancy, breastfeeding or suspected of being pregnant 15)Those judged to be not suitable by the attending physician Second step (maintenance) 1)Symptomatic brain metastasis 2)Accompanied by serious complication in induction therapy 3) Severe drug allergy for PEM or BEM or severe adverse effect in induction therapy
研究者
相似试验
已完成
2 期
A randomized phase II study comparing cisplatin + docetaxel with carboplatin + paclitaxel in patients with Stage III (N 2 positive) non-small-cell lung cancer who receive trimodality treatment consisting of chemoradiotherapy followed by surgery (OLCSG1601)previously untreated non-small-cell lung ccancer, stage III (N2 positive)JPRN-UMIN000024816Okayama Lung Cancer Study Group (OLCSG)80
尚未招募
2 期
ANTS Trial (Australian Neoadjuvant Therapy Study for Non-small Cell Lung Cancer)ACTRN12608000061336Austin Health100
进行中（未招募）
1 期
A Phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line treatment of patients with advancd transitional carcinoma of the urothelium. - SUCCINCTEUCTR2007-007591-42-GBCardiff University63
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusEUCTR2019-000308-13-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)180
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusOropharyngeal Squamous Cell CarcinomaMedDRA version: 20.1Level: LLTClassification code 10079785Term: Oropharyngeal squamous cell carcinoma stage IVSystem Organ Class: 100000004864EUCTR2019-000308-13-ITEuropean Organisation for Research and Treatment of Cancer (EORTC)180